Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 176 - 200 of 10294 in total

Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis ... [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Halothane

A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
Approved
Vet approved
Matched Description: … Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents …
Matched Categories: … Hypotensive Agents ... Agents that produce hypertension ... Central Nervous System Agents …

Fenofibrate

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
Approved
Matched Categories: … Hypolipidemic Agents ... Agents Causing Muscle Toxicity ... Lipid Modifying Agents ... Lipid Regulating Agents ... Lipid Modifying Agents, Plain …

Birch bark extract

Birch bark extract is rich in triterpenoids with beneficial biological and pharmacological activities. Some of the compounds identified in it include betulin, lupeol, betulinic acid, oleanolic acid, and erythrodiol. Birch bark extract is obtained from the white part of the birch tree bark, and the main species of trees used...
Approved
Experimental
Matched Description: … wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the skin ... [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. ... [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness …
Matched Categories: … Anti-Inflammatory Agents ... Anti-inflammatory Agents, Miscellaneous …

Vigabatrin

Vigabatrin is an analog of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the...
Approved
Matched Description: … used extensively until 1997, when an association with vision loss became apparent. ... Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in ... [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was …
Matched Categories: … GABA Agents ... Neurotransmitter Agents ... Central Nervous System Agents …

Brexpiprazole

Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared...
Approved
Investigational
Matched Description: … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called ... [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. ... [A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated …
Matched Categories: … Antidepressive Agents ... Antidepressive Agents Indicated for Depression ... Dopamine Agents ... Antipsychotic Agents ... Serotonin Agents …

D-glucose

Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through...
Approved
Investigational
Vet approved
Matched Description: … It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms ... [T28] The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation …
Matched Categories: … Flavoring Agents ... Sweetening Agents …

Oxyphenonium

A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]
Approved
Matched Description: … It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms …
Matched Categories: … Autonomic Agents ... Cholinergic Agents ... Anticholinergic Agents ... Agents producing tachycardia ... Neurotransmitter Agents …

Quizartinib

Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated ... [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Gepirone

Gepirone, an azapirone, is a pharmacologic analog of buspirone that acts selectively on the pre- and post-synaptic 5HT1A receptors. Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. It was not until an extended-release formulation of...
Approved
Investigational
Matched Description: … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand ... Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and ... It was not until an extended-release formulation of gepirone was made available that gepirone became …
Matched Categories: … Antidepressive Agents ... Anti-Anxiety Agents ... Serotonin Agents ... Tranquilizing Agents ... Neurotransmitter Agents …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Description: … of Neurofibromatosis type 1 (NF-1) in a limited age group. ... NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. ... [A193533] Selumetinib was approved by the FDA on April 10, 2020. …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Dalbavancin

Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents …

Technetium Tc-99m red blood cells

Technetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding. It is clinically useful in early detection and localization of bleeding sites, and...
Approved

Potassium hydroxide

Potassium hydroxide, also known as lye is an inorganic compound with the chemical formula KOH. Also commonly referred to as caustic potash, it is a potent base that is marketed in several forms including pellets, flakes, and powders. It is used in various chemical, industrial and manufacturing applications. Potassium hydroxide...
Approved
Matched Description: … Potassium hydroxide, also known as _lye_ is an inorganic compound with the chemical formula _KOH_. ... [L1943] In addition to the above uses, potassium hydroxide is also used in making soap, as an electrolyte …

Copper Cu-64

Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable. It is used in molecular radiotherapy and positron emission tomography.
Approved

Ethosuximide

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Approved
Matched Description: … An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types …
Matched Categories: … Antiarrhythmic agents ... Agents causing hyperkalemia ... QTc Prolonging Agents ... Bradycardia-Causing Agents ... Central Nervous System Agents …

Poa pratensis pollen

Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.
Approved

Phleum pratense pollen

Phleum pratense pollen allergenic extract is used in allergenic testing.
Approved
Investigational

Eteplirsen

Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. It consists of a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and RNA. Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory...
Approved
Investigational
Matched Description: … [A244930] It is caused by loss-of-function mutations in the DMD gene coding for dystrophin, an essential ... Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] ... Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy …

Sucralfate

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a cytoprotective agent, protecting cells in...
Approved
Matched Description: … It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. ... considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents …
Matched Categories: … Anti-Ulcer Agents ... Gastrointestinal Agents …

Medrogestone

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … It was conceived as an alternative for an orally effective contraceptive option. ... [L1118] It was never approved by the FDA. ... [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …

Tegafur-uracil

Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Approved
Investigational
Matched Description: … [A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or ... It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. ... Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and …

Silanol

Silanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.
Approved
Matched Description: … Silanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and …

Tinidazole

A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Approved
Investigational
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Antiparasitic Agents ... Antitrichomonal Agents …

Romidepsin

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Approved
Investigational
Matched Description: … Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment …
Matched Categories: … Antineoplastic Agents ... QTc Prolonging Agents ... Highest Risk QTc-Prolonging Agents ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 176 - 200 of 10294 in total